MP24-16 PSOAS MUSCLE VOLUME IS A PREDICTIVE MARKER OF APPETITE LOSS IN PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE
نویسندگان
چکیده
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-16 PSOAS MUSCLE VOLUME IS A PREDICTIVE MARKER OF APPETITE LOSS IN PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE Eiji Kashiwagi, Keisuke Monji, Masaki Shiota, Ken Lee, Takashi Matsumoto, Ario Takeuchi, Junichi Inokuchi, and Masatoshi Eto KashiwagiEiji Kashiwagi More articles by this author , MonjiKeisuke Monji ShiotaMasaki Shiota LeeKen Lee MatsumotoTakashi Matsumoto TakeuchiArio Takeuchi InokuchiJunichi Inokuchi EtoMasatoshi View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract WITHDRAWN © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e418-e418 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...
منابع مشابه
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
RATIONALE PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses. PATIENT CONCERNS However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined. DIAGNOSES AND INTERVENTATIONS Medical records of patients with documented mCRPC treated with enzalutamide between Septemb...
متن کاملEnzalutamide for patients with metastatic castration-resistant prostate cancer
OBJECTIVE To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and castration-resistant prostate cancer. Data from FDA product labels were also used. STUDY SELEC...
متن کاملWhat is the most appropriate test in detecting prostate cancer in patients with intermediate prostate specific antigen levels?
Abstract Background: Regarding the variety of tests present for detecting and also screening prostate cancer and also bearing in mind the advantages and disadvantages of these tests we decided to re-evaluate these tests (total prostate specific antigen and all of its modifications) in detecting prostate cancer in men with intermediate serum PSAlevels. Methods: Following a cross se...
متن کاملContribution of 68Ga-PSMA PET/CT to targeting volume delineation of prostate cancer treated with conformal radiation therapy: Which SUV threshold is appropriate?
Introduction: Prostate-specific membrane antigen (PSMA) has been demonstrated as a promising tool for specific imaging of prostate cancer (PCa) via positron emission tomography-computed tomography (PET/CT) scanning. Radiation treatment planning (RTP) based on 68Ga-PSMA PET/CT scanning can also lead to some decision modifications. The specific goal o...
متن کاملChange in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Urology
سال: 2021
ISSN: ['0022-5347', '1527-3792']
DOI: https://doi.org/10.1097/ju.0000000000002015.16